We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+49.94%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
Cap. Flow
-$3.86M
Cap. Flow %
-0.12%
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$23.2M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$14.5M
3
CYTK icon
Cytokinetics
CYTK
+$13.8M
4
DYN icon
Dyne Therapeutics
DYN
+$13.8M
5
ZLAB icon
Zai Lab
ZLAB
+$11M

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$21.1M
2
CGON icon
CG Oncology
CGON
+$20M
3
IRON icon
Disc Medicine
IRON
+$12.9M
4
COGT icon
Cogent Biosciences
COGT
+$12.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VALN
26
Valneva
VALN
$610M
$28M 0.84%
2,291,666
+833,333
+57% +$7.12M
RNAM
27
DELISTED
Avidity Biosciences
RNAM
$27.2M 0.82%
625,000
– –
ASND icon
28
Ascendis Pharma A/S
ASND
$16.3B
$26.5M 0.79%
133,333
– –
ALKS icon
29
Alkermes
ALKS
$7.95B
$21M 0.63%
700,647
-300,000
-30% -$8.46M
MREO
30
Mereo BioPharma
MREO
$40.3M
$19.4M 0.58%
9,440,112
– –
AKRO
31
DELISTED
Akero Therapeutics
AKRO
$17.4M 0.52%
366,784
– –
PCVX icon
32
Vaxcyte
PCVX
$8.9B
$17.1M 0.51%
474,405
– –
EOLS icon
33
Evolus
EOLS
$587M
$16.2M 0.48%
2,630,665
+195,115
+8% +$1.52M
DSGN icon
34
Design Therapeutics
DSGN
$946M
$14.7M 0.44%
1,953,547
– –
IMCR icon
35
Immunocore
IMCR
$1.89B
$14M 0.42%
384,782
– –
ACAD icon
36
Acadia Pharmaceuticals
ACAD
$5.02B
$13.1M 0.39%
+613,837
New +$14.5M
JBIO
37
Jade Biosciences
JBIO
$1.33B
$12.2M 0.37%
1,413,280
-358,836
-20% -$2.93M
ASMB icon
38
Assembly Biosciences
ASMB
$694M
$11.7M 0.35%
+456,249
New +$10M
ADVM
39
DELISTED
Adverum Biotechnologies
ADVM
$9.41M 0.28%
2,077,431
+1,008,187
+94% +$2.97M
TVTX icon
40
Travere Therapeutics
TVTX
$6.19B
$9.37M 0.28%
392,092
-610,000
-61% -$11.5M
NAMSW icon
41
NewAmsterdam Pharma Warrant
NAMSW
$8.56M 0.26%
500,333
– –
ENGN icon
42
enGene Therapeutics
ENGN
$122M
$7.9M 0.24%
+1,157,380
New +$5.28M
AUTL
43
Autolus Therapeutics
AUTL
$623M
$7.54M 0.23%
4,623,324
– –
MGNX icon
44
MacroGenics
MGNX
$263M
$5.34M 0.16%
3,175,665
– –
SLN
45
Silence Therapeutics
SLN
$834M
$5.03M 0.15%
970,130
– –
ALLO icon
46
Allogene Therapeutics
ALLO
$698M
$4.8M 0.14%
3,868,750
– –
CBIO
47
Crescent Biopharma
CBIO
$659M
$3.25M 0.1%
272,951
-180,734
-40% -$2.4M
CGON icon
48
CG Oncology
CGON
$6.59B
– –
-770,000
Closed -$20M
COGT icon
49
Cogent Biosciences
COGT
$6.02B
– –
-1,734,601
Closed -$12.5M
ELEV
50
DELISTED
Elevation Oncology
ELEV
– –
-5,993,579
Closed -$2.2M
1
2
3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2025 Portfolio in Review

As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
  • Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
  • Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
  • Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.